Monte Rosa Therapeutics, Inc. (GLUE) stock
Close on Nov 17, 2026Market cap $773.79MP/E –Yield –
Earnings
Monte Rosa Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Monte Rosa Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 16, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | $54.40M | +325.0% | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | $9.00M | -61.2% | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | $4.20M | -95.1% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 17, 2026before the open | $2.80M | -95.4% | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | $12.80M | +39.1% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025before the open | $23.20M | +393.6% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | $84.90M | +7618.2% | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 20, 2025before the open | $60.60M | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | $9.20M | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | $4.70M | – | -$0.43 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024before the open | $1.10M | – | -$0.53 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 14, 2024before the open | – | – | -$0.58 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023before the open | – | – | -$0.70 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023before the open | – | – | -$0.71 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023before the open | – | – | -$0.65 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 16, 2023before the open | – | – | -$0.63 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022before the open | – | – | -$0.58 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022before the open | – | – | -$0.57 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 11, 2022before the open | – | – | -$0.51 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 29, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 12, 2021after the close | – | – | -$0.43 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Monte Rosa Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Monte Rosa Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Monte Rosa Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Results
- Results
- News
- Update
- Update
- Update
- Update
- Results
- Update
- Results
See a number that looks wrong?